Insmed Incorporated
INSM
Rang in aandelen
#1117
Insmed Incorporated operates as a biopharmaceutical enterprise focused on... Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Aandeelprijs
$95.24
Marktkapitalisatie
$20.80B
Verandering (1 dag)
-0.06%
Verandering (1 jaar)
-43.28%
Land
US
Handel Insmed Incorporated (INSM)
Categorie
Healthcare
P/S-ratio voor Insmed Incorporated (INSM)
P/S-ratio op October 2026 TTM: 18.77
Volgens de meest recente financiële rapporten en aandelenkoers van Insmed Incorporated is de huidige P/S-ratio (TTM) 18.77. Eind 2023 had het bedrijf een P/S-ratio van 14.26.
P/S-ratiohistoriek voor Insmed Incorporated van 2000 tot 2026
P/S-ratio aan het einde van elk jaar
| Jaar | P/S-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 18.77 | -39.72% |
| 2024 | 31.14 | 118.38% |
| 2023 | 14.26 | 42.32% |
| 2022 | 10.02 | -38.17% |
| 2021 | 16.20 | -18.01% |
| 2020 | 19.76 | 33.56% |
| 2019 | 14.80 | -85.57% |
| 2018 | 102.51 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | -100.00% |
| 2014 | 57.87 | 11.92% |
| 2013 | 51.71 | 0.00% |
| 2012 | 0.00 | -100.00% |
| 2011 | 16.12 | 33.50% |
| 2010 | 12.08 | 27.98% |
| 2009 | 9.44 | 93.34% |
| 2008 | 4.88 | -61.16% |
| 2007 | 12.57 | -85.15% |
| 2006 | 84.64 | -88.45% |
| 2005 | 732.99 | 16.61% |
| 2004 | 628.56 | -10.83% |
| 2003 | 704.88 | 9,371.65% |
| 2002 | 7.44 | -98.25% |
| 2001 | 424.21 | -59.94% |
| 2000 | 1.06K | 0.00% |
P/S-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/S-ratio | Verschil in P/S-ratio | Land |
|---|---|---|---|
| 10.02 | -46.61% |
US
|
|
| 40.55 | 116.02% |
US
|
|
| 3.96 | -78.90% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -45.95% |
NL
|
